# US 2004/0024231 A1 · 17Alpha fluoroalkyl steroids, method for producing the same and pharmaceutical compositions containing said compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0024231 A1
- Document ID: US20040024231A1
- Status: Published application
- Kind: A1
- Application number: 10/381,789
- Filed: 2003-08-12
- Published: 2004-02-05
- Earliest claimed: 2000-09-29
- Inventors: Sven Ring; Guenter Kaufmann; Ralf Wyrwa; Walter Elger
- Web page: https://patentgrep.com/patent/US20040024231A1

## CPC

- C07J 71/0047: {at position 2(3)}
- A61P 5/26: Androgens
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61P 15/16: Masculine contraceptives
- A61P 35/00: Antineoplastic agents
- C07J 1/0037: {the substituent in position 17 alfa being a saturated hydrocarbon group}
- C07J 1/0085: {the substituent in position 17 alfa being a saturated hydrocarbon group}
- C07J 11/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
- C07J 71/0063: {at position 2(3)}
- C07J 71/0084: {Episulfides}
- C07J: STEROIDS (seco-steroids C07C)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to 17α fluoroalkyl steroids of the general formula (I). STEROID (I), wherein R3 represents a group of the formula CnFmHo, wherein n=1, 2, 3, 4, 5 or 6, m>1 and m+o=2n+1. The invention further relates to methods for producing the same and to compositions that contain said compounds. The inventive composition of the general formula (I) possess androgenic activity. 1

## Claims

### Claim 1

17α-fluoroalkyl steroids of general formula (1)
5
in which
R1 stands for a C1-4-alkyl group,
R2 stands for a hydroxy group, a group OC(O)—R20 or OR21, whereby R20 and R21 mean a C1-12-alkyl group, a C3-8-cycloalkyl group, an aryl group or an aryl-C1-4-alkyl group,
R3 stands for a radical of formula CnFmHo, whereby n=1, 2, 3, 4, 5 or 6, m>1 and m+o=2n+1,
R4 and R5 in each case stand for a hydrogen atom, together for a double bond or a methylene bridge,
R5 and R6 each stand for a hydrogen atom, together for a double bond or a methylene bridge,
STEROID stands for a steroidal ABC-ring system of partial formulas A, B, C, D, E and F:
6
whereby an additional double bond can be found in A and C in 1,2-position, and one or two additional double bonds can be found in B in 8,9-position and 11,12-position,
R7 means a hydrogen atom, a halogen atom, a hydroxyl group or a trifluoromethyl group,
X means an oxygen atom, two hydrogen atoms or a hydroxyimino group,
R8 means a hydrogen atom, a methyl or ethyl group,
R9 means a hydrogen atom or a halogen atom or together with R10 stands for a double bond,
R10 means a hydrogen atom, a hydroxyl group, a methyl or ethyl group or together with R9 stands for a double bond,
R11 means a hydrogen atom, a C1-4-alkyl group, a nitrile group, a hydroxy-methylene group or a formyl group,
R12 means a hydrogen atom, a C1-4-alkyl group or a nitrile group,
R11 and R12, in addition to the above-mentioned meanings, together mean a methylene bridge,
R13 means a hydrogen atom or together with R7 means a double bond,
R14 and R15 together stand for a double bond, an oxirane ring, a thiirane ring, a [2,3c]oxadiazole ring, a [3,2c]isoxazole ring or a [3,2c]pyrazole ring,
Y stands for an oxygen or nitrogen atom,
and the wavy lines at R7, R8, R11, R12, R13, R14 and R15 mean that these substituents can be in α- or β-position, and the following compounds are excluded:
17β-Hydroxy-17α-trifluoromethyl-androst-4-en-3-one
17β-Hydroxy-17α-trifluoromethyl-estr-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-estra-4,9-dien-3-one,
17β-Hydroxy-17α-trifluoromethyl-estra-4,9,11-trien-3-one,
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-gona-4,9-dien-3-one and
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-gona-4,9,11-trien-3-one.

### Claim 2 (depends on 1)

17α-Fluoroalkyl steroids according to claim 1, whereby STEROID stands for a steroidal ring system of partial formula A.

### Claim 3 (depends on 1)

17α-Fluoroalkyl steroids according to claim 1, whereby STEROID stands for a steroidal ring system of partial formula B.

### Claim 4 (depends on 1)

17α-Fluoroalkyl steroids according to claim 1, whereby STEROID stands for a steroidal ring system of partial formula C.

### Claim 5 (depends on 1)

17α-Fluoroalkyl steroids according to claim 1, whereby STEROID stands for a steroidal ring system of partial formula D.

### Claim 6 (depends on 1)

17α-Fluoroalkyl steroids according to claim 1, wherebv STEROID stands for a steroidal ring system of partial formula E.

### Claim 7 (depends on 1)

17 α-Fluoroalkyl steroids according to claim 1, whereby STEROID stands for a steroidal ring system of partial formula F.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

17α-Fluoroalkyl steroids according to one of claims 1 to 7, whereby R1 represents a methyl group.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

17α-Fluoroalkyl steroids according to one of claims 1 to 8, whereby R2 means a hydroxy group, a formyloxy group, an acetyloxy group, a propionyloxy group, a butyryloxy group, a [(trans-4-butylcyclohexyl)carbonyl]oxy group, a phenylpropionyloxy group, an iso-butyryloxy group, a heptanyloxy group or an undecanyloxy group.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

17α-Fluoroalkyl steroids according to one of claims 1 to 9, whereby R3 represents a trifluoromethyl group or a pentafluoroethyl group.

### Claim 11 (depends on 1, 2, 3)

17α-Fluoroalkyl steroids according to one of claims 1 to 3 as well as 8 to 10, whereby R8 is a methyl group.

### Claim 12 (depends on 1, 2, 3, 4, 5)

17α-Fluoroalkyl steroids according to one of claims 1 to 5 as well as 8 to 11, whereby R7 represents a fluorine, chlorine or bromine atom, or a trifluoromethyl or hydroxy group.

### Claim 13 (depends on 1, 2)

17α-Fluoroalkyl steroids according to one of claims 1, 2 as well as 8 to 11, whereby R10 represents a hydroxy group.

### Claim 14 (depends on 1, 2)

17α-Fluoroalkyl steroids according to one of claims 1, 2 as well as 8 to 12, whereby R9 is a fluorine atom.

### Claim 15 (depends on 1, 4, 7, 12)

17α-Fluoroalkyl steroids according to one of claims 1, 4, 7 and 12, whereby R11 represents a hydroxymethylene group or a formyl group.

### Claim 16 (depends on 1, 5, 11, 12)

17α-Fluoroalkyl steroids according to one of claims 1, 5, 11 and 12, whereby Y is an oxygen atom.

### Claim 17 (depends on 1)

17α-Fluoroalkyl steroids according to claim 1, namely
17β-Hydroxy-17α-trifluoromethyl-7α-methyl-androst-4-en-3-one,
17β,4-Dihydroxy-17α-trifluoromethyl-androst-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-4-chloro-androst-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-4-bromo-androst-4-en-3-one,
17β-Hydroxy-17α,4-bis(trifluoromethyl)-androst-4-en-3-one,
17β,11β-Dihydroxy-17α-trifluoromethyl-androst-4-en-3-one,
17β,11β-Dihydroxy-17α-tritluoromethyl-9 α-fluoro-androst-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-trifluoromethyl-4-chloro-androsta-1,4-dien-3-one,
17β,4-Dihydroxy-17α-trifluoromethyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17a-trifluoromethyl-7α-methyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-trifluoromethyl-7α-methyl-4-chloro-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-pentailuoroethyl-androst-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-androst-4-en-3-one,
17β,4-Dihydroxy-17α-pentafluoroethyl-androst-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-chloro-androst-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-bromo-androst-4-en-3-one,
17β-Hydroxy-17α-pentailuoroethyl-4-trifluoromethyl-androst-4-en-3-one,
17β,11β-Dihydroxy-17α-pentafluoroethyl-androst-4-en-3-one,
17β,11β-Dihydroxy-17α-pentafluoroethyl-9α-fluoro-androst-4-en-3-one,
17β-Hydroxy-17α-pentatluoroethyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-chloro-androsta-1,4-dien-3-one,
17β,4-Dihydroxy-17α-pentafluoroethyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-trifluoromethyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-4-chloro-androsta-1,4-dien-3-one,
17β-Hydroxy-17α-trifluoromethyl-7α-methyl-estr-4-en-3-one,
17β,4-Dihydroxy-17α-trifluoromethyl-estr-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-4-chloro-estr-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-4-bromo-estr-4-en-3-one,
17β-Hydroxy-17α,4-bis(trifluoromethyl)-estr-4-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-7α-methyl-estra-4,9-dien-3-one,
17β-Hydroxy-17α-trifluoromethyl-7α-methyl-estra-4,9,11-trien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-estr-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-estr-4-en-3-one,
17β,4-Dihydroxy-17α-pentafluoroethyl-estr-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-chloro-estr-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-brorpo-estr-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-4-trifluoromethyl-estr-4-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-estra-4,9-dien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-estra-4,9,11-trien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-estra-4,9-dien-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-estra-4,9,11-trien-3-one,
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-4-chloro-gon-4-en-3-one,
13-Ethyl-17β,4-hydroxy-17α-trifluoromethyl-gon-4-en-3-one
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-7α-methyl-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-7α-methyl-gona-4,9-dien-3-one,
13-Ethyl-17β-hydroxy-17α-trifluoromethyl-7α-methyl-gona-4,9, 11-trien-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-7α-methyl-gon-4-en-3-one,
13-Ethyl-17β,4-dihydroxy-17α-pentafluoroethyl-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-4-chloro-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-4-bromo-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-4-trifluoromethyl-gon-4-en-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-gona-4,9-dien-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-gona-4,9,11-trien-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-7α-methyl-gona-4,9-dien-3-one,
13-Ethyl-17β-hydroxy-17α-pentafluoroethyl-7α-methyl-gona-4,9,11-trien-3-one,
17β-Hydroxy-17α-tnifluoromethyl-5α-androstan-3-one,
17β-Hydroxy-17α-pentafluoroethyl-5α-androstan-3-one,
17β-Hydroxy-17α-trifluoromethyl-7α-methyl-5α-androstan-3-one,
17β-Hydroxy-17α-pentafluoroethyl-7α-methyl-5α-androstan-3-one,
17β-Hydroxy-17α-triuoromethyl-2-hydroxymethylene-5α-androstan-3-one,
17β-Hydroxy-17α-pentafluoroethyl-2-hydroxymethylene-5α-androstan-3-one,
17β-Hydroxy-17α-trifluoromethyl-2α-methyl-5α-androstan-3-one,
17β-Hydroxy-17α-pentafluoroethyl-2α-methyl-5α-androstan-3-one,
17β-Hydroxy-17α-trifluoromethyl-1α-methyl-5α-androstan-3-one,
17β-Hydroxy-17α-pentafluoroethyl-1α-methyl-5α-androstan-3-one,
17β-Hydroxy-17α-trifluorom ethyl-5α-androst-2-ene,
17β-Hydroxy-17α-pentafluoroethyl-5α-androst-2-ene,
17β-Hydroxy-17α-trifluoromethyl-2-methyl-5α-androst-2-ene,
17β-Hydroxy-17α-pentafluoroethyl-2-methyl-5α-androst-2-ene,
17β-Hydroxy-17α-trnfluoromethyl-2-cyano-5α-androst-2-ene,
17β-Hydroxy-17α-pentafluoroethyl-2-cyano-5α-androst-2-ene,
17β-Hydroxy-17α-trifluoromethyl-2-formyl-5α-androst-2-ene,
17β-Hydroxy-17α-pentafluoroethyl-2-formyl-5α-androst-2-ene,
17β-Hydroxy-17α-trifluoromethyl-[2,3 c]oxadiazole-5α-androstane,
17β-Hydroxy-17α-pentafluoroethyl-[2,3c]oxadiazole-5α-androstane,
17β-Hydroxy-17α-trifluoromethyl-[3,2c]isoxazote-5α-androstane,
17β-Hydroxy-17α-pentafluoroethyl-[3,2 c]isoxazole-5α-androstane,
17β-Hydroxy-17α-trifluoromethyl-[3,2c]pyrazole-5α-androstane,
17β-Hydroxy-17α-pentafluoroethyl-[3,2c]pyrazole-5α-androstane,
17β-Hydroxy-17α-trifluoromethyl-2β,3β-epithio-5α-androstane,
17β-Hydroxy-17α-pentafluoroethyl-2β,3β-epithio-5α-androstane,
17β-Hydroxy-17α-trifluoromethyl-2α,3α-epithio-5α-androstane,
17β-Hydroxy-17α-pentafluoroethyl-2α,3α-epithio-5αandrostane,
17β-Hydroxy-17α-trifluoromethyl-2-oxa-5α-androstan-3-one,
17β-Hydroxy-17α-pentafluoroethyl-2-oxa-5α-androstan-3-one,
17β-Hydroxy-17α-trifluoromethyl-5α-androst-1-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-5α-androst-1-en-3-one,
17β-Hydroxy-17α-trifluoromethyl-1-methyl-5α-androst-1-en-3-one,
17β-Hydroxy-17α-pentafluoroethyl-1-methyl-5α-androst-1-en-3-one,
17β-Hydroxy-17α-tritluoromethyl-2-methyl-5α-androst-1-en-3-one and
17β-Hydroxy-17α-pentafluoroethyl-2-methyl-5α-androst-1-en-3-one.

### Claim 18 (depends on 1)

Process for the production of 17α-fluoroalkyl steroids of general formula (I) according to claim 1, characterized in that compounds of general formula (II)
7
in which R1, R4, R5, R6 and STEROID have the meanings given in claim 1, are reacted in the presence of fluoride with perfluoroalk-yltrialkylsilanes, (Alk)3SiCnFmHo, or with fluoroalkyl lithium, LiCnFmHo, or fluoroalkyl Grignard reagents, ZMgCnFmHo, whereby n=1, 2, 4, 5 or 6, n>1 and m+o=2n, Z is a chlorine, bromine or iodine atom, and Alk is a C1-4-alkyl radical.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

Pharmaceutical compositions that contain at least one 17α-fluoroalkyl steroid of general formula (I) according to one of claims 1 to 17, optionally together with pharmaceutically compatible adjuvants and vehicles.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

17α-Fluoroalkyl steroids of formula (I) according to one of claims 1 to 17 for use as therapeutic active ingredients.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

Use of 17α-fluoroalkyl steroids of general formula (I) according to one of claims 1 to 17 for birth control in men, for hormone replacement therapy (HRT) in men and women or for treatment of hormonally induced diseases in men and women, such as, for example, endometriosis, breast cancer or hypogonadism.
